Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab IRDye800 Optical Imaging Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck~* Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.~* Planned standard of care surgery with curative intent for squamous cell carcinoma~* Age ≥ 19 years~* Have life expectancy of more than 12 weeks~* Karnofsky performance status of at least 70% or ECOG/Zubrod level 1~* Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count \> 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range~Exclusion Criteria~* Received an investigational drug within 30 days prior to first dose of panitumumab IRDye800~* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment~* History of infusion reactions monoclonal antibody therapies~* Pregnant or breastfeeding~* Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)~* Magnesium or potassium lower than the normal institutional values~* Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.~* Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis~* TSH \> 13 micro International Units/mL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab IRDye 800 (Type: EXPERIMENTAL): Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).